Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J P Kastelein

Showing results (1-10 of 606) with videos related to

Pageof 61
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|February 20, 2020
[Gene Therapy Office; the Potemkin village of the Ministry of Infrastructure and Water Management]John J P Kastelein
Lancet (London, England)|August 19, 2014
Dyslipidaemia in perspectiveJohn J P Kastelein
Lancet (London, England)|November 3, 2004
Should rosuvastatin be withdrawn from the market?John J P Kastelein
Nature Reviews. Cardiology|September 10, 2014
Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemiaJohn J P Kastelein
The American Journal of Cardiology|December 6, 2007
Refocusing on use of cholesteryl ester transfer protein inhibitorsJohn J P Kastelein
The American Journal of Cardiology|November 18, 2005
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?John J P Kastelein
Cardiovascular Drugs and Therapy|March 26, 2003
Lipoprotein lipase deficiency--rare or common?Valerie Evans, John J P Kastelein
Expert Review of Cardiovascular Therapy|October 19, 2013
PCSK9 and resistin at the crossroads of the atherogenic dyslipidemiaShirya Rashid, John J P Kastelein
Nature Clinical Practice. Cardiovascular Medicine|April 24, 2008
Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemiaMenno Vergeer, John J P Kastelein
The New England Journal of Medicine|August 20, 2015
PCSK9 Inhibitors and Cardiovascular EventsJennifer G Robinson, John J P Kastelein
Pageof 61

Showing results (1-10 of 606) with videos related to

Sort By:
Pageof 61
Nederlands Tijdschrift Voor Geneeskunde|February 20, 2020
[Gene Therapy Office; the Potemkin village of the Ministry of Infrastructure and Water Management]John J P Kastelein
Lancet (London, England)|August 19, 2014
Dyslipidaemia in perspectiveJohn J P Kastelein
Lancet (London, England)|November 3, 2004
Should rosuvastatin be withdrawn from the market?John J P Kastelein
Nature Reviews. Cardiology|September 10, 2014
Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemiaJohn J P Kastelein
The American Journal of Cardiology|December 6, 2007
Refocusing on use of cholesteryl ester transfer protein inhibitorsJohn J P Kastelein
The American Journal of Cardiology|November 18, 2005
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?John J P Kastelein
Cardiovascular Drugs and Therapy|March 26, 2003
Lipoprotein lipase deficiency--rare or common?Valerie Evans, John J P Kastelein
Expert Review of Cardiovascular Therapy|October 19, 2013
PCSK9 and resistin at the crossroads of the atherogenic dyslipidemiaShirya Rashid, John J P Kastelein
Nature Clinical Practice. Cardiovascular Medicine|April 24, 2008
Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemiaMenno Vergeer, John J P Kastelein
The New England Journal of Medicine|August 20, 2015
PCSK9 Inhibitors and Cardiovascular EventsJennifer G Robinson, John J P Kastelein
Pageof 61